Addition of matrix metalloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer

Cancer Research

Volumn 60, Issue 12, 2000, Pages 3207-3211

  Haq, Mahmudul ^a   Shafii, Alexis ^c   Zervos, Emmanuel E ^b   Rosemurgy, Alexander S ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c James A Haley VA Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BATIMASTAT; GEMCITABINE; MATRIX METALLOPROTEINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TUMOR GROWTH; ZYMOGRAPHY;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BODY WEIGHT; CHROMATOGRAPHY, AFFINITY; DEOXYCYTIDINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PHENYLALANINE; THIOPHENES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0034044162     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Landies, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1999. J. Am. Cancer Soc., 49: 8-31, 1999.
2. Regine, W. F., John, W. J., and Mohiuddin, M. Adjuvant therapy for pancreatic cancer: current status. Front. Biosci., 3: E186-E192, 1998.
3. Blaszkowsky, L. Treatment of advanced and metastatic pancreatic cancer. Front. Biosci., 3: E214-E225, 1998.
4. Burris, H. A., III, Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., Nelson, R., Dorr, F, A., Stephen, C. D., and Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 15: 2403-2413, 1997.
5. Koshiba, T., Wada, M., Fujimot, K., Lee, J. U., Kato, M., Doi, R., Shimada, Y., Hosotani, R., Arii, S., and Imamura, M. Activation of MMP-2 and MMP-9 in human pancreatic career tissues and human pancreatic cancer lines. Gastroenterology, 110: A545, 1996.
6. Mignatti, P., and Rifkin, D. B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev., 73: 161-195, 1993.
7. Sang, Q. X. Complex role of matrix metalloproteinases in angiogenesis. Cell Res., 8: 171-177, 1998.
8. Lozonschi, L., Sunamura, M., Kobari, M., Egawa, S., Ding, L., and Matsuno, S. Controlling tumor angiogenesis and metastasis of C26 murine colon adenocarcinoma by a new matrix metalloproteinase inhibitor, KB-R7785, in two tumor models. Cancer Res., 59: 1252-1258, 1999.
9. Zervos, E. E., Norman, J. G., Gower, W. R., Franz, M. G., and Rosemurgy, A. S. Matrix metalloproteinase inhibition attenuates human pancreatic cancer growth in vitro and decreases mortality and tumorigenesis in vivo. J. Surg. Res., 69: 367-371. 1997.
10. Rosemurgy, A. S., Harris, J., Langleben, A., Casper, E., Goode, S., and Rasmussen, H. Marimastat in patients with advanced pancreatic cancer: a dose-finding study. Am. J. Clin. Oncol., 22: 247-252, 1999.
11. Butera, J., Malachovsky, M., Rathore, R., and Safran, H. Novel approaches in the development for the treatment of pancreatic cancer. Front. Biosci., 3: E226-E229, 1998.
12. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J., and Hoffman, R. M. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res., 54: 4726-4728, 1994.
13. Hertel, L. W., Boder, G. B., Kroin, J. S., Rinzel, S. M., Poore, G. A., Todd, G. C., and Grindey, G. B. Evaluation of the antitumor activity of gemcitabine (2′,2′-difluorodeoxycytidine). Cancer Res., 50: 4417-4422, 1990.
14. Heinemann, V., Hertel, L. W., Grindey, G. B., and Plunkett, W. Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res., 48: 4024-4031, 1998.
15. Ghandhi, V., and Plunkett, W. Modulatory activity of 2′,2′-difluorodeoxycytidine on phosphorylation and cytotoxicity of arabinosyl nucleosides. Cancer Res., 50: 3675-3680, 1990.
16. Huang, P., Chubb, S., Hertel, L. W., Grindey, G. B., and Plunkett, W. Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res., 51: 6110-6117, 1991.
17. Gower, W. R., Risch, R. M., Godellas, C. V., and Fabri, P. J. HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell. Dev. Biol., 30A: 151-161, 1994.
18. Brown, P. D., Bloxidge, R. E., Stuart, N. S., Gatter, K. C., and Carmichael, J. Association between expression of activated 72 kD gelatinase and tumor spread in non-small-cell lung carcinoma. J. Natl. Cancer Inst., 85: 574-578, 1993.
19. Zervos, E. E., Shafii, A. E., Haq, M., and Rosemurgy, A. S. Matrix metalloproteinase inhibition suppresses MMP-2 activity and activation of Pane-1 cells in vitro. J. Surg. Res., 84: 162-167, 1999.
20. Zervos, E. E., Shafii, A. E., and Rosemurgy, A. S. Matrix metalloproteinase (MMP) inhibition selectively decreases type II MMP activity in a murine model of pancreatic cancer. J. Surg. Res., 81: 65-68, 1999.
21. Merriman, R. L., Hertel, L. W., Schultz, R. M., Houghton, P. J., Houghton, J. A., Rutherford, P. G., Tanzer, L. R., Boder, G. B., and Grindey, G. B. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft model. Invest. New Drugs, 14: 243-247, 1996.
22. Giavazzi, R., Garofalo, A., Ferri, C., Lucchini, V., Bone, E. A., Chiari, S., Brown, P. D., Nicolette M. I., and Taraboetti, G. Batimastat, a synthetic inhibitor of matrix metalloproteinases, potentiates the antitumor activity of cisplatin in ovarian carcinoma xenografts. Clin. Cancer Res., 4: 985-992, 1998.
23. Parson, S. L., Watson S. A., and Steele, R. J. Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites. Eur. J. Surg. Oncol., 23: 526-531, 1997.
24. Wojtowicz Praga, S., Torri, J., Johnson, M., Steen, V., Marshall, J., Ness, E., Dickson, R., Sale, M., Rasmussen, H. S., Chiodo, T. A., and Hawkins, M. J. Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 16: 2150-2156, 1998.